Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?

• Status: Unknown status
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Aspirin (ASA) has been shown, in an animal model, to attenuate the ototoxic properties of cisplatin. The researchers plan to investigate this in patients undergoing cisplatin chemotherapy.

The researchers hypothesise that low-dose aspirin can prevent cisplatin induced ototoxicity in the clinical setting.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Health Network, Toronto
• Treatments: Aspirin; Cisplatin

Criteria

Inclusion Criteria:

• Patients undergoing cisplatin treatment for the following malignancies:

• germ-cell

• bladder

• head and neck (Only head and neck patients requiring only 2 cycles of post-operative chemo-radiotherapy, and therefore not requiring a gastrostomy tube, will be enrolled.)

• Over 18 years of age

• Normal otoscopic examination

• Informed consent

Exclusion Criteria:

Patients with the following will be excluded:

• Not able to grasp the study implications or unable to consent.

• History of peptic ulcer disease

• Severe renal impairment (U&E, Cr clearance)

• Haemophilia

• Severe hepatic impairment

• Cerebrovascular haemorrhage

• Acute gout

• Hypersensitivity to NSAIDs